BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 17111120)

  • 21. Activity and toxicity of oxaliplatin and bolus fluorouracil plus leucovorin in pretreated colorectal cancer patients: a phase II study.
    Ferraresi V; Giampaolo MA; Gabriele A; Mansueto G; Buccilli A; Giannarelli D; Ciccarese M; Gamucci T
    J Exp Clin Cancer Res; 2005 Jun; 24(2):187-96. PubMed ID: 16110750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Outpatient chemotherapy with continuous infusion of 5-fluorouracil (CI 5-FU) and intravenous bolus leucovorin (IVB LV) in advanced gastrointestinal cancer: the second report].
    Tsuji Y; Yoshihito H; Nakamura T; Watanabe Y; Nakayama N; Ohi M; Kawanishi J; Handa H; Honjo K; Uehara S
    Gan To Kagaku Ryoho; 1995 Dec; 22 Suppl 4():439-46. PubMed ID: 8849290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.
    Liu ZF; Guo QS; Zhang XQ; Yang XG; Guan F; Fu Z; Wang MY
    Am J Clin Oncol; 2008 Jun; 31(3):259-63. PubMed ID: 18525305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
    Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N
    J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
    Oh SY; Kwon HC; Seo BG; Kim SH; Kim JS; Kim HJ
    Acta Oncol; 2007; 46(3):336-41. PubMed ID: 17450469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule.
    Pazdur R; Lassere Y; Diaz-Canton E; Ho DH
    Cancer Invest; 1998; 16(3):145-51. PubMed ID: 9541627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
    Seo HY; Kim DS; Choi YS; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):433-9. PubMed ID: 18398608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients.
    Rosati G; Cordio S; Tucci A; Blanco G; Bordonaro R; Reggiardo G; Manzione L
    Oncology; 2005; 69(2):122-9. PubMed ID: 16118508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer.
    Shibahara K; Yamamoto M; Kakeji Y; Sakata H; Maehara Y
    Anticancer Res; 2008; 28(3B):1779-83. PubMed ID: 18630459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
    Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
    Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic arterial infusion combined with oral UFT/UZEL systemic chemotherapy for unresectable liver metastasis of colorectal cancer.
    Tsutsumi S; Yamaguchi S; Tsuboi K; Fukasawa T; Tabe Y; Asao T; Kuwano H
    Hepatogastroenterology; 2008; 55(85):1419-22. PubMed ID: 18795703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxaliplatin fractionated over two days with bimonthly leucovorin and 5-fluorouracil in metastatic colorectal cancer.
    Recchia F; Rea S; Nuzzo A; Lalli A; Di Lullo L; De Filippis S; Saggio G; Biondi E; Massa E; Mantovani G
    Anticancer Res; 2004; 24(3b):1935-40. PubMed ID: 15274380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
    J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.
    Ghosn M; Farhat F; Kattan J; Younes F; Moukadem W; Nasr F; Chahine G
    Am J Clin Oncol; 2007 Feb; 30(1):15-20. PubMed ID: 17278889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitomycin C and UFT/leucovorin as salvage treatment in patients with advanced colorectal cancer.
    Michalaki V; Gennatas S; Gennatas C
    J BUON; 2010; 15(2):270-3. PubMed ID: 20658720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
    J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
    Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
    Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma.
    Chen JS; Chao Y; Yang TS; Chou WC; Chen LT; Lee KD; Lin YC
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):151-7. PubMed ID: 19455334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma.
    Laudani A; Gebbia V; Leonardi V; Savio G; Borsellino N; Cusimano MP; Calabria C; Stefano R; Agostara B
    Anticancer Res; 2004; 24(2C):1139-42. PubMed ID: 15154638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC).
    Cavanna L; Artioli F; Codignola C; Lazzaro A; Rizzi A; Gamboni A; Rota L; RodinĂ² C; Boni F; Iop A; Zaniboni A
    Am J Clin Oncol; 2006 Aug; 29(4):371-5. PubMed ID: 16891864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.